1-[[4-(trifluoromethyl)phenyl]methylsulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine | 958694-01-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[[4-(trifluoromethyl)phenyl]methylsulfonyl]-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine
• CAS: 958694-01-4
• 化学式: C₁₈H₁₇F₆N₃O₂S
• 分子量: 453.408
• InChiKey: SVKLEODLNBNVAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  61.9
• 氢给体数：
  0
• 氢受体数：
  11

文献信息

• 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF
  申请人：Jacobson Peer B.

  公开号：US20110159005A1

  公开（公告）日：2011-06-30

  A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme.
• US8871208B2
  申请人：——

  公开号：US8871208B2

  公开（公告）日：2014-10-28
• [EN] 1,4-DISUBSTITUTED PIPERAZINE AND 1,4-DISUBSTITUTED AZEPANE AS 11 -BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS<br/>[FR] 1,4-DISUBSTITUÉES PIPÉRAZINE ET 1,4-DISUBSTITUÉES AZÉPANE INHIBITRICES DE LA 11 -BÉTA-HYDROXYSTÉROID DÉSHYDROGÉNASE 1
  申请人：ASTRAZENECA AB

  公开号：WO2007135427A1

  公开（公告）日：2007-11-29

  [EN] Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11ßHSD1, processes for making them and pharmaceutical compositions comprising them are described.
  [FR] L'invention porte sur des composés de formule (I) dans laquelle les groupes variables sont définis dans la description, sur leur utilisation comme inhibiteurs de la 11ßHSD1, sur leurs procédés d'obtention, et sur des préparations pharmaceutiques les comprenant.
• [EN] 11-ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA 11-?-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1 (11B-HSD1) ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2011068927A2

  公开（公告）日：2011-06-09

  A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteroporosis, comprising administering an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme.